Xeris Biopharma To Host XP‑8121 Program Overview Detailing Phase 3 Study And Commercial Opportunity; Topline Results Expected In Late 2028; FDA Approval And Launch Anticipated In 2030
Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030The Company expects XP-8121 peak net revenue potential of $1 to $3
Xeris is testing a new medicine called XP-8121 and plans to show results in late 2028, with hopes for approval and sale by 2030. When watching this company, you can look for updates on whether their testing stays on schedule—that tells you if their medicine is progressing or hitting bumps.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.